Trial reportPloS one2016
Uremic Solutes in Chronic Kidney Disease and Their Role in Progression.
Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Interventions for improving health literacy in people with chronic kidney disease.The Cochrane database of systematic reviews · 2022Pooled it
- Multifaceted Role of Microbiota-Derived Indole-3-Acetic Acid in Human Diseases and Its Potential Clinical Application.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Uncovering the Link Between Kynurenic Acid Pathway and Kidney Failure.Kidney international reports · 2025Article
- Kynurenines and aerobic exercise capacity in chronic kidney disease: A cross-sectional and longitudinal study.PloS one · 2025Article
- Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- A robust, accurate, sensitive LC-MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells.Biomedical chromatography : BMC · 2022Article
- Blood Thiol Redox State in Chronic Kidney Disease.International journal of molecular sciences · 2022Review
- A metabolomics approach identified toxins associated with uremic symptoms in advanced chronic kidney disease.Kidney international · 2022Article
- Antibiotic Exposure AggravatesFrontiers in immunology · 2022Article
- Local Inhibition of Indoleamine 2,3-Dioxygenase Mitigates Renal Fibrosis.Biomedicines · 2021Article
- Plasma Metabolome and Lipidome Associations with Type 2 Diabetes and Diabetic Nephropathy.Metabolites · 2021Article
- The Kynurenine Pathway in Acute Kidney Injury and Chronic Kidney Disease.American journal of nephrology · 2021Review
- Rapid Preparation of a Large Sulfated Metabolite Library for Structure Validation in Human Samples.Metabolites · 2020Article
- The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology.Clinical pharmacology and therapeutics · 2020Review
- Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study.PloS one · 2020Article
- Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2019Observational
- Uraemic syndrome of chronic kidney disease: altered remote sensing and signalling.Nature reviews. Nephrology · 2019Review
- Coordinate regulation of systemic and kidney tryptophan metabolism by the drug transporters OAT1 and OAT3.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo date, over 150 possible uremic solutes have been listed, but their role in the progression of CKD is largely unknown. Here, the association between a selected panel of uremic solutes and progression in CKD patients was investigated.
methodsPatients from the MASTERPLAN study, a randomized controlled trial in CKD patients with a creatinine clearance between 20 and 70 ml/min per 1.73m2, were selected based on their rate of eGFR decline during the first five years of follow-up. They were categorized as rapid (decline >5 ml/min per year) or slow progressors. Concentrations of eleven uremic solutes were obtained at baseline and after one year of follow-up. Logistic regression was used to compare the odds for rapid to slow progression by uremic solute concentrations at baseline. Variability in uremic solute levels was assessed using scatter plots, and limits of variability were calculated.
resultsIn total, 40 rapidly and 40 slowly progressing patients were included. Uremic solutes were elevated in all patients compared to reference values for healthy persons. The serum levels of uremic solutes were not associated with rapid progression. Moreover, we observed substantial variability in solute levels over time.
conclusionsElevated concentrations of uremic solutes measured in this study did not explain differences in rate of eGFR decline in CKD patients, possibly due to lack of power as a result of the small sample size, substantial between patient variability, and variability in solute concentrations over time. The etiology of intra-individual variation in uremic solute levels remains to be elucidated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.